Abstracts tagged "Economics"

Abstract Number: 2609 • ACR Convergence 2024
Drivers of Infliximab Biosimilar Uptake: A Comparative Analysis of New Biosimilar Initiations versus Switching in a National Rheumatology Registry
Eric Roberts¹, Nick Bansback², Chien-Wen Tseng³, Steve Shiboski⁴, Jing Li⁵, Gabriela Schmajuk⁶ and Jinoos Yazdany⁷, ¹University of California, San Francisco, SF, CA, ²University of British Columbia, Vancouver, BC, Canada, ³University of Hawai'i John A. Burns School of Medicine, Honolulu, ⁴University of California, San Francisco, San Francisco, ⁵University of California, San Francisco, San Francisco, CA, ⁶UCSF / SFVA, San Francisco, CA, ⁷UCSF, San Francisco, CA
Background/Purpose: Biosimilars hold promise for reducing pharmaceutical expenditures, however uptake has lagged. We analyzed the variability in new biosimilar starts and switching from bio-originator infliximab…
Abstract Number: 2682 • ACR Convergence 2024
The Forgotten Costs of SLE: Estimating Indirect Costs in a National SLE Cohort
Ann E. Clarke¹, Yvan St-Pierre², Megan Barber¹, Sasha Bernatsky³, Evelyne Vinet⁴, Christian Pineau⁵, Murray Urowitz⁶, Dafna Gladman⁷, Christine Peschken⁸, John Hanly⁹, Alexandra Legge¹⁰ and Paul Fortin¹¹, ¹Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²McGill University Health Center, Montreal, QC, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Centre, Montreal, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Self employed, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, ¹⁰Dalhousie University, Halifax, NS, Canada, ¹¹Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada
Background/Purpose: Economic analyses of SLE often include only direct healthcare costs. Indirect costs, particularly those attributable to lost productivity in unpaid labour, are often overlooked,…
Abstract Number: 0173 • ACR Convergence 2023
Review of Published Literature Reporting Economic Burden of Treatment Switching in Rheumatoid Arthritis
Peter C. Taylor¹ and Jenya Antonova², ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Compass Strategy and Research, Inc., San Francisco, CA
Background/Purpose: For rheumatoid arthritis (RA) American College of Rheumatology (ACR) recommends the treating to target approach, starting with conventional synthetic antirheumatic drugs (DMARDs). ACR advises…
Abstract Number: 0242 • ACR Convergence 2023
Venous Thromboembolism in Patients with Gout in the US
Alka Mithal¹, Maanek Sehgal¹, Brian LaMoreaux² and Gurkirpal Singh¹, ¹ICORE, Woodside, CA, ²Horizon Therapeutics, Deerfield, IL
Background/Purpose: Venous thromboembolism (VTE), manifested by deep venous thrombosis (DVT) and pulmonary embolism (PE), is a common medical problem with an estimated incidence of 1–2…
Abstract Number: 0335 • ACR Convergence 2023
Meta-Analysis of the Cost-Effectiveness of Social Media Advertising as a Recruitment Tool
Vladislav Tsaltskan¹, Roel Baez² and Gary Firestein¹, ¹University of California San Diego, San Diego, CA, ²UC San Diego Health, San Diego, CA
Background/Purpose: Recruitment of study participants is challenging and can incur significant costs, particularly for studies of rheumatic disease or other rare conditions. Social media advertising…
Abstract Number: 0966 • ACR Convergence 2023
The Burden of Oligoarticular Psoriatic Arthritis in the United States
Abisola Olopoenia¹, Ashley Martin², Kate Orroth³, Cynthia Deignan⁴, Myriam Cordey⁵ and Dafna Gladman⁶, ¹Cerner Enviza, North Kansas City, MO, ²BluePath Solutions, Los Angeles, CA, ³Amgen, Inc., Manhattan Beach, CA, ⁴Amgen, Inc., Agoura Hills, CA, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with oligoarticular psoriatic arthritis (oligo PsA), defined as four or less joints involved, often do not meet criteria for entry in trials of…
Abstract Number: 2002 • ACR Convergence 2023
Cost-Effectiveness Analysis of Sequential Treatment with Abaloparatide Followed by Alendronate in US Women and Men with Multiple Previous Fractures
Mickael Hiligsmann¹, Stuart Silverman², Andrea J Singer³, Yamei Wang⁴, Leny Pearman⁴, John Caminis⁴ and Jean-Yves Reginster⁵, ¹Maastricht University, Maastricht, Netherlands, ²Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, ³MedStar Georgetown University Hospital, Washington, DC, ⁴Radius Health, Inc., Boston, MA, ⁵University of Liège, Liège, Belgium
Background/Purpose: Patients with multiple previous fractures are at very high risk of subsequent fractures. Common treatment strategies for these patients include generic alendronate (ALN) monotherapy…
Abstract Number: 2169 • ACR Convergence 2023
Cost-utility of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-economic Analysis of the Towards the Lowest Efficacious Dose Trial
Joanna Kedra¹, Benjamin Granger², Lina El Houari³, Florence Tubach⁴ and Bruno Fautrel⁵, ¹Sorbonne Université, IPLESP, and Pitié-Salpêtrière Hospital, Paris, France, ²Sorbonne Université, INSERM, and Pitié Salpêtrière Hospital, Paris, France, ³Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France, ⁴Centre de pharmaco-épidémiologie de l'APHP, Paris, France, ⁵Sorbonne Université APHP, Paris, France
Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) progressive tapering is a real opportunity in people living with rheumatoid arthritis (RA) having achieved remission both from…
Abstract Number: 2266 • ACR Convergence 2023
Direct Health Care Costs Differ by SLE Autoantibody Machine Learning Clusters in an International Inception
May Choi¹, Karen Costenbader², Marvin Fritzler¹, Yvan St. Pierre³, Murray Urowitz⁴, John G. Hanly⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Juanita Romero-Diaz⁸, Jorge Sanchez-Guerrero⁹, Sasha Bernatsky³, Daniel Wallace¹⁰, David Isenberg¹¹, Anisur Rahman¹², Joan Merrill¹³, Paul R. Fortin¹⁴, Dafna Gladman¹⁵, Ian Bruce¹⁶, Michelle Petri¹⁷, Ellen Ginzler¹⁸, Mary Anne Dooley¹⁹, Rosalind Ramsey-Goldman²⁰, Susan Manzi²¹, Andreas Jonsen²², Graciela S Alarcón²³, Ronald van Vollenhoven²⁴, Cynthia Aranow²⁵, Meggan MacKay²⁵, Guillermo Ruiz-Irastorza²⁶, S. Sam Lim²⁷, Murat Inanc²⁸, Kenneth Kalunian²⁹, Soren Jacobsen³⁰, Christine Peschken³¹, Diane L. Kamen³², Anca Askanase³³, Jill Buyon³⁴ and Ann Clarke³⁵, ¹University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁷Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ⁸Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁹University Health Network, Toronto, ON, Canada, ¹⁰Cedars-Sinai Medical Center, Los Angeles, CA, ¹¹University College London, London, United Kingdom, ¹²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ¹³Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ¹⁶University of Manchester, Manchester, United Kingdom, ¹⁷Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ¹⁸SUNY Downstate Health Sciences University, Brooklyn, NY, ¹⁹Raleigh Neurology Associates, Chapel Hill, NC, ²⁰Northwestern University, Chicago, IL, ²¹Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²²Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ²³Heersink School of Medicine. The University of Alabama at Birmingham, Birmingham, AL, ²⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ²⁵Feinstein Institutes for Medical Research, Manhasset, NY, ²⁶Hospital Universitario Cruces, Barakaldo, Spain, ²⁷Emory University, Atlanta, GA, ²⁸Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ²⁹University of California San Diego, La Jolla, CA, ³⁰Rigshospitalet, Copenhagen, Denmark, ³¹University of Manitoba, Winnipeg, MB, Canada, ³²Medical University of South Carolina, Charleston, SC, ³³Columbia University Medical Center, New York, NY, ³⁴NYU Grossman School of Medicine, New York, NY, ³⁵University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada
Background/Purpose: Using machine learning, we identified 4 patient clusters based on longitudinal autoantibody profiles in an international SLE inception cohort, which were predictive of disease…
Abstract Number: 0120 • ACR Convergence 2023
Incidence and Prevalence of Systemic Lupus Erythematosus in Urban China, 2013-2017: A Nationwide Population-based Study
Mucong Li¹, Chaiquan Li², Mengzhuo Cao³, Ke Lu², Chanyuan Wu³, Jiuliang zhao¹, Qian Wang⁴, Xinping Tian¹, Xun Tang², Mengtao Li¹, xiaofeng Zeng⁴ and Pei Gao², ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Peking University, Beijing, China, ³Peking Union Medical College Hospital, Beijing, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Systemic lupus erythematosus (SLE) is becoming a public health concern because of increasing disease and economic burdens. Epidemiological information on SLE, especially its incidence…
Abstract Number: 0155 • ACR Convergence 2023
Cost Analysis of Subcutaneous Methotrexate Compared to Oral Methotrexate Treatment for Rheumatoid Arthritis
Aniket Kawatkar, David Yi, Erika Estrada and Cecilia Portugal, Kaiser Permanente Southern California, Pasadena, CA
Background/Purpose: Rheumatoid Arthritis (RA)patients who switch from oral to subcutaneous methotrexate (MTX) may experience better response to treatment due to increased bioavailability, enhanced tolerability, increased…
Abstract Number: 0159 • ACR Convergence 2023
Understanding the Economic Impact of Autoimmune Eye Disease in the United States
Krati Chauhan¹, Steven Scaife² and Michael Buhnerkempe¹, ¹Southern Illinois University - School of Medicine, Springfield, IL, ²Southen Illinois University - School of Medicine., Springfield, IL
Background/Purpose: Eye involvement is an important cause of morbidity in rheumatology patients. Inflammatory eye diseases include conditions like scleritis, uveitis, retinitis and orbital inflammation. The…
Abstract Number: 0166 • ACR Convergence 2023
Annual Economic Burden for Patients with Familial Hypophosphatemia in the United States
Zhiyi Li¹, Elizabeth Marchlewicz², Danae Black², Hana Schwartz², Yang Zhao¹ and Erik Imel³, ¹Kyowa Kirin North America, Bedminster, NJ, ²Merative, Cambridge, MA, ³Indiana University School of Medicine, Indianapolis, IN
Background/Purpose: Familial hypophosphatemia (FH) is most commonly due to phosphate regulating endopeptidase X-linked (PHEX) gene mutations resulting in renal phosphate wasting, which leads to rickets,…
Abstract Number: 0168 • ACR Convergence 2023
What Are the Characteristics of a Cost-Effective Psoriatic Arthritis Biomarker Test? An Early Health Technology Assessment
Nick Bansback¹, Alex Tam², Dafna Gladman³, Vathany Kulasingam⁴, Eldon Spackman⁵ and Vinod Chandran⁶, ¹University of British Columbia, Vancouver, BC, Canada, ²Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁴Department of Laboratory Medicine and Pathobiology, University of Toronto and Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Initiating treatment in patients with psoriasis (PsO) who have unrecognized Psoriatic arthritis (PsA) may slow disease progression and improve long-term outcomes. Several candidate biomarkers…
Abstract Number: 0169 • ACR Convergence 2023
Added Value of Anti-HMGCR and Anti-SRP Antibodies in the Diagnosis of Immune Mediated Necrotizing Myopathy: An Outcome and Cost Comparison from the USA Perspective
Alejandro Figueroa-Lara¹, Mary Ann Aure² and Carmen Andalucia¹, ¹Werfen, San Diego, CA, ²Werfen, Chula Vista, CA
Background/Purpose: Immune-mediated necrotizing myopathies (IMNM) is a subgroup of immune-mediated myopathies (IMM). The diagnosis of IMNM relied on the presence of proximal muscle weakness, high…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].